Below are six executive resignations affecting the pharmaceutical industry that were announced this month:

Two Georgia pharmacists were charged July 15 with diversion of drugs to nonpatients and healthcare fraud, the U.S. Justice Department said.

The Netherlands is testing a "no cure, no pay" reimbursement model for expensive cancer drugs, according to Medscape.

Johnson & Johnson plans to test an experimental HIV vaccine in the U.S. and Europe, according to Bloomberg.

GlaxoSmithKline plans to hire former AstraZeneca and Novartis finance director Jonathan Symonds to manage its breakup, according to the Financial Times.

Foster City, Calif.-based drugmaker Gilead Sciences has agreed to a $5.1 billion deal with Galapagos, under which Gilead will pay to increase its stake in the Belgian biotechnology company, according to The Wall Street Journal.

Many generic drugs in Medicare Part D are "wildly overpriced," according to an analysis from drug pricing research firm 46brooklyn.  

Ten hospitals and health systems posted job listings seeking pharmacy leaders in the last week.

Altaire Pharmaceuticals is recalling 30 over-the-counter products sold at CVS due to sterility concerns. 

Lunds & Byerlys, a supermarket chain in the Minneapolis-St. Paul region, will shut down all of its pharmacies due to significant losses, according to Fox 9.